To determine if BRD4 and IRS2 inhibitors can modulate the BMMCs immunosuppressive cancer microenvironment into an immunocompetent one, we measured the expression of several key tumor‐related immune molecules at the transcriptional and translational levels. The gene discussed is BRD4; the disease is neoplasm.